Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment.

Pediatric nephrology (Berlin, Germany) - 1 Apr 2012

Quinlan Catherine, Guegan Katie, Offiah Amaka, Neill Richard O', Hiorns Melanie P, Ellard Sian, Bockenhauer Detlef, Hoff William Van't, Waters Aoife M

Abstract excerpt

Inactivating mutations in phosphate-regulating endopeptidase (PHEX) cause X-linked hypophosphatemic rickets (XLHR) characterized by phosphaturia, hypophosphatemia, bony deformities, and growth retardation. We assessed the efficacy of combined calcitriol and orally administered phosphate (Pi) therapy on longitudinal growth in relation to age at treatment onset in a retrospective, single-center review of children...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Density Conservation Agents
Share to Calcitriol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Familial Hypophosphatemic Rickets

Share to Genetic Diseases, X-Linked

Share to Growth and Development

Share to Infant

Share to PHEX Phosphate Regulating Neutral Endopeptidase

Share to Phosphates

Source

Identifiers

PMID: 22101457
DOI: 10.1007/s00467-011-2046-z

Genes

PHEX

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment.PMID 22101457Read ↗

Long-term effect of conventional phosphate and calcitriol treatment on metabolic recovery and catch-up growth in children with PHEX mutation.Semantic proximity Read ↗

Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population.Semantic proximity Read ↗

Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population.Semantic proximity Read ↗

Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene.Semantic proximity Read ↗

X-linked hypophosphatemia: The medical expert's challenges and the patient's concerns on their journey with the disease.Semantic proximity Read ↗

X-linked hypophosphataemic rickets in children: clinical phenotype, therapeutic strategies, and molecular background.Semantic proximity Read ↗

X-linked hypophosphataemic rickets: Report of a novel PHEX mutation and cinacalcet as adjuvant therapy in the mineral metabolism control.Semantic proximity Read ↗

Expert consensus on evidence-based recommendations for the diagnosis, treatment, and follow-up of X-linked hypophosphatemic rickets (XLH)Semantic proximity Read ↗

Hypophosphatemic rickets: etiology, clinical features and treatment.Semantic proximity Read ↗

Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.Semantic proximity Read ↗

The Metabolic Bone Disease X-Linked Hypophosphatemia: Case Presentation, Pathophysiology and PharmacologySemantic proximity Read ↗

The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.